Project Grant R00MH130688

Award Date 9/1/24
Completion Date 8/31/27
Dollars Obligated $498K
Federal Grant Program
93.242
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This $629,844 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research on the role of the ventral tegmental area (VTA) in motivated behavior. The project aims to elucidate the function of VTA circuits using an integrative approach combining optogenetics, in vivo electrophysiology, and quantitative behavioral measures. Key objectives include understanding how VTA GABA projection neurons...
This federal Project Grant award of $606,029.00 from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) will support research at the University of Massachusetts Medical School (UMass Medical) to investigate the neurocircuitry underlying motivated reward-seeking behavior in response to stress. The key goals of the research are to: 1) Determine if a subpopulation of GABAergic neurons in the medial habenulo-interpeduncular (MHB-IPN) axis...
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $816,063 to The Trustees of Columbia University in the City of New York to conduct research on the neural mechanisms underlying how social stimuli elicit motivated behavior. The key focus of the research is to understand how neural representations of social rank information, such as dominant and submissive social cues, converge onto brain...
This Project Grant award, valued at $390,687, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The award will support research at New York University (NYU) to investigate how the brain regions of the orbitofrontal cortex, dorsal striatum, and basolateral amygdala interact to support belief updating and context-dependent decision making. The researchers will perform simultaneous electrophysiological recordings and use...
This Project Grant award of $396,250 from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants (CFDA 93.242) program, will support research at Vanderbilt University to investigate the regulation of metabotropic glutamate receptor (mGluR) activity by protein-protein interactions. The research aims to: 1) test a suite of agonists, positive allosteric modulators (PAMs), and negative allosteric modulators (NAMs) for activity at mGluR7 with and without the protein...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $206,955.00 to the University of North Carolina at Chapel Hill (UNC-CH) to conduct research on the neural mechanisms underlying negative affective states associated with substance use disorders and depression. The research aims to understand the global impact of learned negative affect on large-scale brain network activity in rats. The project will...
This federal Project Grant award of $201,250 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to New York University (NYU) for the period of June 1, 2025 to May 31, 2027. The grant supports research on the synaptic organization of cholinergic interneurons in the nucleus accumbens, which plays a key role in motivated behaviors and is disrupted in substance use disorder. The project aims to characterize how diverse...
This Project Grant award of $781,032, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research on the interplay between norepinephrine and dopamine circuits in the brain and their role in sex differences in reward and aversion. The research will be conducted by The Research Foundation for the State University of New York (RF SUNY) from August 2025 through April 2030. Key objectives include mapping the anatomical...
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), supports research to investigate the role of metabotropic glutamate receptor signaling in modulating glutamatergic neurotransmission and plasticity in brain regions implicated in schizophrenia. The $217,818 award, effective from September 9, 2025, to September 8, 2027, will be conducted by Vanderbilt University. The key objectives are to use pharmacological...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $613,017.00 to the University of California, Los Angeles (UCLA) to conduct research on the interdependent relationship between dopamine signaling and temporal processing in the ventral striatum. The project aims to examine how dopamine dynamics and striatal neural activity are involved in learning the timing of reward delivery, with a focus on...

BALANCING MOTIVATION THROUGH VTA GABA/GLUTAMATE CO-TRANSMISSION - PROJECT SUMMARY UPDATES: I AM MOVING TO A NEW POSITION AT DARTMOUTH COLLEGE AS AN INDEPENDENT, TENURE-TRACK ASSISTANT PROFESSOR IN THE DEPARTMENT OF PSYCHOLOGICAL AND BRAIN SCIENCES. HERE I WILL CONDUCT THE R00 PHASE EXPERIMENTS AND DEVELOP MY OWN INDEPENDENT RESEARCH PROGRAM. THE OVERALL AIMS OF THE R00 PHASE HAVE NOT CHANGED FROM THE K99 PROPOSAL. IDENTIFYING THE NEURAL CIRCUIT MECHANISMS UNDERLYING BOTH HOMEOSTATIC AND UNCONTROLLED MOTIVATION ARE CRUCIAL FOR DEVELOPING MORE TARGETED AND EFFECTIVE THERAPEUTIC TREATMENTS FOR NEUROPSYCHIATRIC DISORDERS LIKE MAJOR DEPRESSION OR BIPOLAR DISORDER. WITHIN MESOLIMBIC BRAIN REWARD CIRCUITRY, THE VENTRAL TEGMENTAL AREA (VTA) IS A MAJOR REGULATOR OF BOTH REWARD AND AVERSION. WHILE GENERALLY REDUCED TO ITS DOPAMINE PROJECTION NEURONS, THE VTA ALSO CONTAINS NEURONS THAT CO-RELEASE INHIBITORY GABA AND EXCITATORY GLUTAMATE AND, SIMILAR TO DOPAMINE PROJECTIONS, CAN MODULATE MOTIVATION. HOWEVER, THE FUNCTIONAL ROLE OF THIS GABA/GLUTAMATE CO-RELEASE IS STILL NOT WELL UNDERSTOOD, AND MAJOR QUESTIONS REGARDING THEIR ROLE IN POSITIVE VS. NEGATIVE REINFORCEMENT REMAIN. IN PARTICULAR, WHY WOULD NEURONS SIMULTANEOUSLY SEND AN INHIBITORY AND EXCITATORY SIGNAL? DURING THE R00 PHASE, I WILL UNIFY MY PRIOR EXPERTISE WITH NEWLY ACQUIRED SKILLS TO DETERMINE THE PHYSIOLOGICAL AND BEHAVIORAL ROLE OF A NEWLY-DESCRIBED VTA GABA/GLUTAMATE PROJECTION TO AMYGDALA. USING IN VIVO CALCIUM IMAGING, I WILL FIRST MONITOR ACTIVITY OF VTA GABA/GLUTAMATE TERMINALS IN AMYGDALA DURING AN EFFORT-BASED INSTRUMENTAL SUCROSE TASK (AIM 1), AND WILL THEN IDENTIFY THE NET EFFECT OF OPTOGENETICALLY STIMULATING VTA GABA/GLUTAMATE TERMINALS ON CELL-DEFINED AMYGDALA POPULATIONS (AIM 2). THESE RESULTS WILL SIGNIFICANTLY EXPAND OUR UNDERSTANDING OF THE ROLE OF VTA CO-RELEASE IN COMPLEX MOTIVATED BEHAVIOR RELEVANT TO MODELS OF BIPOLAR DISORDER AND DEPRESSION, AND WILL CRUCIALLY PAVE THE WAY FOR MORE TARGETED APPROACHES THAT FORM THE BASIS MY INDEPENDENT RESEARCH PROGRAM.

Posted 8/23/24